Top

BMC Health Services Research

Published in:

Open Access 01-12-2021 | Research article

Assessing the prices and affordability of oncology medicines for three common cancers within the private sector of South Africa

Authors: Phyllis Ocran Mattila, Zaheer-Ud-Din Babar, Fatima Suleman

Published in: BMC Health Services Research | Issue 1/2021

Abstract

Background

Prices of cancer medicines are a major contributor to the cost of treatment for cancer patients and the comparison of these cost needs to be assessed.

Objectives

To assess the prices of cancer medicines for the three most common cancers ((breast, prostate and colorectal) in the private healthcare sector of South Africa.

Methods

The methodology was adapted from the World Health Organization (WHO)/ Health Action International (HAI) methodology for measuring medicine prices. The Single Exit Price (SEP) variations between product types of the same medicine between the highest- and lowest-priced product and between Originator Brand (OB) and its Lowest Priced Generic (LPG) of the same medicine brand was compared, as of March 2020. The affordability of those medicines for cancer usage based on treatment affordability in relation to the daily wage of the unskilled Lowest-Paid Government Worker (LPGW) was also determined. Also, a comparison of the proportion of the population below the poverty line (PL) before (I_pre) and after (I_post) procurement of the cancer medicines was determined.

Results

SEP Price differences ranged from 25.46 to 97.33% between highest- and lowest-priced products and a price variation of 72.09% more for the OB than the LPG medicine, except for one LPG that was more expensive than the OB. Affordability calculations showed that All OB treatments for all three cancers (breast, prostate and colorectal), except for paclitaxel 300 mg (0.2 days wage) and Fluorouracil (Fluroblastin) 500 mg (0.3 days wage) costs respectively were more than 1 day’s wage, with patients diagnosed with colorectal cancer needing 32.5 days wages in order to afford a standard course of treatment for a month.

Conclusion

There was a considerable variation in the price of different brands of cancer medicines available in the South African private sector.

World Health Organization. Facts Sheet. 2018. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed 5 July 2020.

International Agency for Research on Cancer. South Africa: Source: Globocan 2020. The global Cancer observatory, the World Health Organization, December 2020. https://cansa.org.za/files/2021/02/IARC-Globocan-SA-2020-Fact-Sheet.pdf.

Staff Writer. Massive rise in cancer related treatment in South Africa – these are the most common types among men and women. Businesstech, 8 February 2020. https://businesstech.co.za/news/lifestyle/371244/massive-rise-in-cancer-related-treatment-in-south-africa-these-are-the-most-common-types-among-men-and-women/.

World Health Organization. Technical Report: Pricing of cancer medicines and its impacts. Geneva: World Health Organization. 2018.

Worldometer. South African Population. https://www.worldometers.info/world-population/south-africa-population/. Accessed 12 April 2021.

Macrotrends. South Africa GNI Per Capita 1962–2021. https://www.macrotrends.net/countries/ZAF/south-africa/gni-per-capita. Accessed 12 April 2021.

World Bank. Poverty and shared prosperity 2018: piecing together the poverty puzzle. Washington, DC: World Bank; 2018.

Jolliffe, Dean, and Espen Beer Prydz. Estimating International Poverty Lines from Comparable National Thresholds. The Journal of Economic Inequality 14(2):185–98.

Niens LM, Cameron A, Van de Poel E, Ewen M, Brouwer WBF, et al. Quantifying the impoverishing effects of purchasing medicines: a cross-country comparison of the affordability of medicines in the developing world. PLoS Med. 2010;7(8):e1000333. https://doi.org/10.1371/journal.pmed.1000333.CrossRefPubMedPubMedCentral

10.

World Health Organization. World Health Statistics 2020: Monitoring health for the SDGs. https://www.who.int/gho/publications/world_health_statistics/2020/en/.

11.

Suleman F, Gray A. Pharmaceutical Policy in South Africa. In: Pharmaceutical policies in South Africa. In: Babar Z, editor. Pharmaceutical Policy in Countries with Developing Healthcare Systems. Springer International Publishing; 2017.CrossRef

12.

Gray A, Suleman F. Pharmaceutical pricing in South Africa. In: Babar Z, editor. Pharmaceutical Prices in the 21st Century. Springer International Publishing; 2015.

13.

South African National Department of Health. National Medicine Policy of South Africa. Pretoria: Department of Health; 1996.

14.

Gray A, Suleman F, Pharasi B. South Africa’s National Medicine Policy: 20 years and still going. South African Health Review. 2017;1:49–58 https://hdl.handle.net/10520/EJC-c80c69129.

15.

Republic of South Africa. Medicines and Related Substances Control Amendment Act (90 of 1997). Government Gazette Vol. 390, No. 18505, Cape Town, 12 December 1997.

16.

Discovery Health Medical Scheme. Integrated annual report. Johannesburg, Discovery Health. 2012.

17.

Niëns LM, Van de Poel E, Cameron A, Ewen M, Laing R, Brouwer WBF. Practical measurement of affordability: an application to medicines. Bull World Health Organ. 2012;90(3):219–27. https://doi.org/10.2471/BLT.10.084087.CrossRefPubMedPubMedCentral

18.

World Health Organization, Health Action International. Measuring medicine prices, availability, affordability and price components. 2nd edition. Geneva: World Health Organization. 2008. Updated July 2020. https://haiweb.org/what-we-do/price-availability-affordability/collecting-evidence-on-medicine-prices-availability/.

19.

South African Department of Health. South African Medicine Price Registry Database of Medicine Prices. Pretoria: National Department of Health. 2019. http://www.mpr.gov.za/PublishedDocuments.aspx#DocCatId=21. Accessed 24 August 2020.

20.

Datapharm Ltd. The electronic medicines compendium (emc). https://www.medicines.org.uk/emc. .

21.

National Comprehensive Cancer Network. Clinical guidelines in practical oncology: NCCN guidelines 2020. https://www.nccn.org/professionals/physician_gls/recently_updated.aspx.

22.

Management Sciences for Health. International Medical Products Price Indicator Guide. Cambridge, Massachussetts: Management Sciences for Health. 2016. https://mshpriceguide.org/en/home/. Accessed 19 August 2020.

23.

Niëns L.M., Brouwer W.B.F Measuring the affordability of medicines: importance and challenges. Health Policy 2013; 112: 45–52, 1-2, DOI: https://doi.org/10.1016/j.healthpol.2013.05.018.

24.

South African Government. Employment and Labour on new National Minimum Wage rate. Department of Employment and Labour. 24 February 2020. https://www.gov.za/speeches/new-nmw-base-rate-come-effect-march-%E2%80%93-department-employment-and-labour-24-feb-2020-0000. Accessed 12 April 2021.

25.

Google. Google exchange rate 12 September 2020. https://www.bing.com/search?q=convert+usd+to+zar&form=EDGTCT&qs=CA&cvid=b9d76661c67540b98c2e68e872cca9d9&cc=US&setlang=en-US. Accessed 12 September 2020.

26.

The World Bank Group. World development indicators. http://wdi.worldbank.org/table/4.8. .

27.

Kolasani B. P., Malathi D. C, Ponnaluri R.R. Variation of Cost among Cancer Medicines Available in Indian Market 2016. DOI: https://doi.org/10.7860/JCDR/2016/22384.8918, Variation of Cost among Anti-cancer Drugs Available in Indian Market.

28.

Cuomo R.E., Seidman R. L, Mackey T.K. Country and regional variations in purchase prices for essential cancer medication 2017. DOI https://doi.org/10.1186/s12885-017-3553-5, 17, 1, 566.

29.

Vogler S, Vitry A, Babar Z-U-D. Cancer medicines in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. Lancet Oncol. 2016;17(1):39–47. https://doi.org/10.1016/S1470-2045(15)00449-0.CrossRef

30.

Salmasi S, Lee KS, Ming LC, Neoh CF, Elrggal ME, Babar ZU, et al. Pricing appraisal of cancer medicines in the south east Asian, Western Pacific and East Mediterranean Region. BMC Cancer. 2017;17:903.CrossRef

31.

Faruqui N., Martiniuk A., Sharma A., Sharma C., Rathore B., Arora R. S, Joshi R. Evaluating access to essential medicines for treating childhood cancers: a medicines availability, price and affordability study in New Delhi, India. 2018. BMJ Glob Health 2019;4: e001379. doi:https://doi.org/10.1136/bmjgh-2018-001379, 2.

32.

Gelband H, Sankaranarayanan R, Gauvreau CL, Horton S, Anderson BO, Bray F, et al. Costs, affordability, and feasibility of an essential package of cancer control interventions in low-income and middle-income countries: key messages from disease control priorities, 3rd edition. Lancet. 2016;387(10033):2133–44. https://doi.org/10.1016/S0140-6736(15)00755-2.CrossRefPubMed

33.

Babar, ZUD. Ten recommendations to improve pharmacy practice in low and middle-income countries (LMICs). J Pharm Policy Pract. 2021;14 (6). https://doi.org/10.1186/s40545-020-00288-2.

34.

Bateman C. Attacking ‘prejudice’ against generics could save SA billions. S Afr Med J. 2015;105(12):1004–5. https://doi.org/10.7196/SAMJ.2015.v105i12.10317.CrossRefPubMed

35.

Babar ZUD, Ibrahim MIM, Singh H, Bukahri NI, Creese A. Evaluating medicine prices, availability, affordability, and price components: implications for access to medicines in Malaysia. PLoS Med. 2007;4(3):e82. https://doi.org/10.1371/journal.pmed.0040082.CrossRefPubMedPubMedCentral

36.

Saqib A, Iftikhar S, Sarwar MR. Availability and affordability of biologic versus non-biologic cancer medicines: A cross-sectional study in Punjab, Pakistan. BMJ Open. 2018;8(6).

37.

Sarwar MR, Iftikhar S, Saqib A. Availability of cancer medicines in public and private sectors, and their affordability by low, middle and high-income class patients in Pakistan. BMC Cancer. 2018;18(1):14. https://doi.org/10.1186/s12885-017-3980-3.CrossRefPubMedPubMedCentral

38.

Islam A, Akhter T. Eden. Cost of treatment for children with acute lymphoblastic leukemia in Bangladesh 2015. J Cancer Policy. 2015;6:37–43. https://doi.org/10.1016/j.jcpo.2015.10.002.CrossRef

39.

Goldstein DA, Clark J, Tu Y, Zhang J, Fang F, Goldstein R, et al. A global comparison of the cost of patented cancer medicines in relation to global differences in wealth. Oncotarget. 2017;8(42):71548–55. https://doi.org/10.18632/oncotarget.17742.CrossRefPubMedPubMedCentral

40.

Cherny NI, Sullivan R, Torode J., Saar M., Eniu A. The European Society for Medical Oncology (ESMO) International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe. Annals of Oncology. 2017; 28: 2633–2647. doi:https://doi.org/10.1093/annonc/mdx521. 2017.

41.

London School of Economics. Tender loving care? Purchasing medicines for continuing therapeutic improvement and better health outcomes. 2016. http://eprints.lse.ac.uk/67824/. Accessed 10 Nov 2016.

42.

Saltz LB. Perspectives on cost and value in cancer care. JAMA Oncol. 2015;2:1–3.

Title: Assessing the prices and affordability of oncology medicines for three common cancers within the private sector of South Africa
Authors: Phyllis Ocran Mattila
Zaheer-Ud-Din Babar
Fatima Suleman
Publication date: 01-12-2021
Publisher: BioMed Central
Published in: BMC Health Services Research / Issue 1/2021
Electronic ISSN: 1472-6963
DOI: https://doi.org/10.1186/s12913-021-06627-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Assessing the prices and affordability of oncology medicines for three common cancers within the private sector of South Africa

Abstract

Background

Objectives

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objectives

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

How is organisational fit addressed in Australian entry level midwifery job advertisements

Exploring utilisation of the allied health assistant workforce in the Victorian health, aged care and disability sectors

A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany

Regional variation of potentially avoidable hospitalisations in Switzerland: an observational study

When time matters: a qualitative study on hospital staff’s strategies for meeting the target times in cancer patient pathways

Patient characteristics and outcome in three different working models of home-based rehabilitation: a longitudinal observational study in primary health care in Norway